A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Robenacoxib-D5 | CAS 2012598-81-9 - Request Quote

Picture of Robenacoxib-D5

Robenacoxib-D5

SZ CAT No:SZ-R070D01
CAS No
2012598-81-9
Mol.F.
C16H8D5F4NO2
Mol.Wt.
332.3
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Robenacoxib-D5 is chemically 2-(5-(Ethyl-d5)-2-((2,3,5,6-tetrafluorophenyl)amino)phenyl)acetic acid. Robenacoxib-D5 is supplied with detailed characterization data compliant with regulatory guideline. Robenacoxib-D5 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Robenacoxib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 2012598-81-9

Purchase 2012598-81-9

Order 2012598-81-9

Enquire 2012598-81-9

price of 2012598-81-9

2012598-81-9 Supplier

2012598-81-9 Manufacturer

2012598-81-9 Exporter

buy high quality Robenacoxib-D5

Purchase Robenacoxib-D5

Robenacoxib-D5 suppliers

Robenacoxib-D5 manufacturers

Robenacoxib-D5 price

Order Robenacoxib-D5

Enquire Robenacoxib-D5

Robenacoxib-D5 cost

Robenacoxib-D5 Supplier

Robenacoxib-D5 Distributor

Robenacoxib-D5 for Method Validation

Robenacoxib Reference Standard

Robenacoxib-D5 for ANDA Filing

Robenacoxib-D5 for Forced Degradation Studies

Robenacoxib-D5 Identification Standards

Robenacoxib-D5 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,